- CB 2679d/ISU 304 is a high potency recombinant Factor IX in development for prophylaxis in patients with Hemophilia B.
- The trial will be conducted by Catalyst’s partner, ISU Abxis (KOSDAQ: 086890) in South Korea.
Catalyst
Slingshot members are tracking this event:
Catalyst Bioscience's CB 2679d/ISU 304 high potency Factor IX for Hemophilia B, is expected to enter a Phase 1/2 proof of concept subcutaneous trial in the first quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CBIO | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 14, 2017
Occurred Source:
http://ir.catalystbiosciences.com/phoenix.zhtml?c=254141&p=irol-newsArticle&ID=2280849
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cb 2679d/isu 304, Factor Ix Therapy, Hemophilia B
